Iovance Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. And we're pleased to have Iovance Biotherapeutics with us. We have Maria Fardis, President and CEO here. And with that, Maria, thanks for joining us.
Questions & Answers
And to start, adoptive cell therapy is a rapidly expanding field. And can you just talk about your choice of using TILs to target cancer? And how this is differentiated, I guess, from the other approaches that we're seeing with CAR Ts, TCRs and some of the others? And are there particularly -- particular indications here that you see as more appropriate to be addressed with TILs? Or do you see -- and where do you see widespread potential of this modality? Lots of questions in one.
Thank you, Salveen. Can I confirm you can
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |